Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-α: A synergistic correlation?

Cancer

Volumn 89, Issue 7, 2000, Pages 1482-1489

  Kozuch, Peter ^a   Talpaz, Moshe ^a   Faderl, Stefan ^a   O'Brien, Susan ^a   Freireich, Emil J ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myelogenous leukemia; Femoral head osteonecrosis; Interferon ; Toxicity

Indexed keywords

ALPHA INTERFERON; CYTARABINE;

ADULT; ARTICLE; ASEPTIC NECROSIS; AVASCULAR NECROSIS; CANCER SURVIVAL; CASE REPORT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; FEMALE; FEMUR HEAD; HUMAN; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTOSIS; WEIGHT BEARING;

ADULT; ANTINEOPLASTIC AGENTS; CASE REPORT; FEMALE; FEMUR HEAD NECROSIS; HUMAN; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGE;

EID: 0034306872     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001001)89:7<1482::AID-CNCR10>3.0.CO;2-T     Document Type: Article

References (49)

1. Chronic myelogenous leukemia: Biology and therapy
2. Chronic myelogenous leukemia: Update on biology and treatment
3. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome positive patients
4. Chronic myelogenous leukemia: A concise update
5. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
6. UK Medical Research Council randomized, multicentre trial of interferon-α nl for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response
7. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
8. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia: The German CML Study Group
9. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
10. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
11. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low dose cytarabine
12. Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha
13. Immune-mediated and unusual complications during interferon alpha therapy in chronic myelogenous leukemia
14. Avascular necrosis of the femoral head
15. Avascular necrosis of bone after renal transplantation
16. Avascular necrosis of the femoral head secondary to corticosteroid therapy for graft versus host disease after marrow transplantation: Effective therapy with hip arthroplasty
17. Aseptic bone/bone marrow necrosis in leukemia
18. Avascular bone necrosis in an untreated case of chronic myelogenous leukemia
19. Avascular femoral head necrosis in pediatric cancer patients
20. Avascular necrosis of the femoral head as a complication of chronic myelogenous leukemia
21. Thrombocytosis in chronic granulocytic leukemia: Incidence and clinical significance
22. Hyperviscosity in chronic granulocytic leukemia
23. Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group
24. Clinical course of essential thrombocythemia in 147 cases
25. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients
26. Controlled and uncontrolled thombocytosis. Its clinical role in essential thrombocythemia
27. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
28. A prospective study of hemostatic parameters in relation to the clinical course of myeloproliferative disorders
29. A reversible defect of platelet PDGF content in myeloproliferative disorders
30. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disease
31. Clinical applications of research on angiogenesis
32. Treatment of pulmonary hemangiomatosis with recombinant interferon alpha-2a
33. Interferon alpha-2a therapy for life-threatening hemangiomas of infancy [errata in N Engl J Med 1994;330-300, 1995;333:595-6]
34. Role of impairment of blood supply of the femoral head in the pathogenesis of idiopathic osteonecrosis
35. Is avascular necrosis of the femoral head the result of inhibition of angiogenesis?
36. Regulation of bovine microvascular cell proteolytic properties by inhibitors of angiogenesis
37. Mechanism of action of angiogenic steroids: Suppression of plasminogen activator inhibitor synthesis
38. Angiogenesis: Models and modulators
39. Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip
40. Hypofibrinolysis: A common cause of osteonecrosis
41. Autoimmune phenomena associated with cutaneous aseptic necrosis during interferon-alpha treatment for chronic myelogenous leukemia
42. Role of cytokines in the process of tumor angiogenesis
43. Alteration in bone marrow adherent layer growth factor expression: A novel mechanism of chronic myelogenous leukemia progression
44. Interleukin 1: The first interleukin
45. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone
46. Corticosteroid-induced avascular necrosis: A clinical study of seventy-seven patients
47. Multiple joint osteonecrosis following short-term steroid therapy case report
48. Association of alcohol intake, cigarette smoking, and occupational status with the risk of idiopathic osteonecrosis of the femoral head
49. Disease states affecting both liver and bone